Biotechnology

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

A recent scientific review links low glutathione to brain disease. A new supplement claims to solve the delivery problem. Is this the future of cognitive health?

Artelo Biosciences executes a reverse stock split to fight delisting, but will the financial maneuver be enough to fund its promising drug pipeline?

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

As Galapagos pivots its strategy, it brings in a new HR chief to build the high-performing culture crucial for its next chapter of innovation.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

New preclinical data shows Quanta Therapeutics' inhibitors remain potent against cancers that have developed resistance to advanced pan-RAS treatments.

With a new SVP of Global Sales, Slingshot Biosciences is poised to scale its synthetic cell mimic technology, targeting the booming cell therapy market.

The firm's new ISO 42001 certification signals a major shift towards verifiable, trustworthy AI for the highly regulated life sciences industry.

A new multi-year deal gives RNAi leader Alnylam access to Helix's vast genomic and clinical data, aiming to redefine the speed of drug discovery.

With data from 150M patients, SEQSTER's new platform promises to accelerate drug development, improve trial diversity, and make research-ready data a reality.

A new FDA program offers a lifeline for patients with rare ROSAH syndrome, accelerating Drug Farm's promising first-in-class therapy.

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

AI drug discovery firm Proxima appoints three titans of science to its board, signaling a major push in proximity therapeutics to rewrite medicine's rules.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.